INDICATIONS

Nplate® is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Nplate® is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.


Nplate® is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Nplate® should not be used in an attempt to normalize platelet counts.

  ... Read More 

Attention: Effective 1/01/2025, Nplate® Has A New HCPCS Code ("J-Code") and Dose Descriptor ("Billing/Service Units")

  • For Dates of Service 1/1/2025 onwards, Use J-Code J2802, injection, romiplostim, 1 microgram and bill service units in multiples of 1 unit = 1 mcg. Please update your processes accordingly.
  • Find full details and additional information here: J-Code flashcard

Nplate® Has the Highest Percentage of Patient Claims With $0 OOP Costs vs Oral Agents* and Broad Coverage (88%)1,2

74% of Nplate® (romiplostim) Claims Have $0 Out-of-Pocket Costs for the Patient vs 60% for Oral Agents2,*

*Based on an analysis from 2021 to 2022 for Commercial and Medicare patient claims combined. Oral OOP percent is a weighted average claim for eltrombopag, avatrombopag, and fostamatinib disodium hexahydrate.2

OOP, out-of-pocket.

We're right here,
right when you need us

Personalized support that you and your patients can count on across Amgen therapies.

Connect with us live:

Call 866-264-2778

Monday through Friday — 9:00 AM to 8:00 PM ET

HCP support center

HCP Support Center

Our Amgen® SupportPlus Representatives can assist with issues around patient coverage, prior authorizations, co-pay programs, and more.

Benefits Verification

  • Verify patient’s insurance plan coverage details
  • Prior Authorization Requirements

  • Provide payer-specific prior authorization forms
  • Amgen SupportPlus Customer Portal

  • A tool for managing patient benefits verifications and more
  • Submit, store, and retrieve benefit verifications electronically
  • Visit myAmgenPortal.com to register and submit forms online

Amgen® access specialists

Field Reimbursement Specialists

A Field Reimbursement Specialist can provide coverage and access resources to support your patients.

Contact your Field Reimbursement Specialist for support that includes:

  • Navigating prior authorization, appeals, and fulfillment processes
  • Educating on payer requirements and necessary documentation for individual patient support
  • Answers to general questions about Amgen SupportPlus programs and other available resources
Financial support

Financial Support

We know every patient has unique needs. And we’re here to provide financial support information and resources, regardless of their current financial situation or what type of insurance they have.

Learn more about how Amgen SupportPlus can help your patients access their prescribed medication. Visit AmgenSupportPlus.com to learn more.

Amgen® SupportPlus Co-Pay Program

Amgen® SupportPlus Co-Pay Program

The Amgen SupportPlus Co-Pay Program may help eligible patients with private or commercial insurance lower their out-of-pocket costs.

  • Pay as little as $0* out-of-pocket for each dose
  • Can be applied to deductible, co-insurance, and co-payment*
  • No income eligibility requirement

Encourage your patients with private or commercial insurance to check eligibility and enroll.

*Eligibility criteria and program maximums apply. See AmgenSupportPlus.com/Copay for full Terms and Conditions.

Amgen® Nurse Partners

Amgen® Nurse Partners

Amgen Nurse Partners can offer support and provide information about resources to help patients access their prescribed medication.

Amgen Nurse Partners can provide support, including:

  • Guidance on resources that may help lower out-of-pocket medication costs
  • Assistance to help your patients stay on track with their medication
  • Answers to questions about Amgen SupportPlus

Patients can connect with an Amgen Nurse Partner by enrolling in Amgen SupportPlus in two ways:

  • Download and have the patient complete the Amgen SupportPlus Enrollment Form found on AmgenSupportPlus.com and fax to 1-888-407-9787
  • Call 866-264-2778 to enroll by phone

Amgen Nurse Partners are only available to patients that are prescribed certain Amgen products. They are not part of your patient’s treatment team and do not provide medical advice, nursing, or case management services. Amgen Nurse Partners will not inject patients with Amgen medications. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

Amgen® Therapy Locator logo

Amgen Therapy Locator™

Use this searchable database to locate alternative injection sites where Nplate® can be administered to your patients*

*The information on this website is reported by independent third-party sites that administer or deliver treatment to patients. It is not comprehensive of all sites that handle the therapies listed, and Amgen does not confirm accuracy or otherwise endorse any of these sites.

Connect with us

Monday through Friday — 9:00 AM to 8:00 PM ET

Important Safety Information

Risk of Progression of Myelodysplastic Syndromes to Acute Myelogenous Leukemia

  • In Nplate® (romiplostim) clinical trials of patients with myelodysplastic syndromes (MDS) and severe thrombocytopenia, progression from MDS to acute myelogenous leukemia (AML) has been observed.
  • Nplate® is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than ITP.

Thrombotic/Thromboembolic Complications

  • Thrombotic/thromboembolic complications may result from increases in platelet counts with Nplate® use. Portal vein thrombosis has been reported in patients with chronic liver disease receiving Nplate®.
  • To minimize the risk for thrombotic/thromboembolic complications, do not use Nplate® in an attempt to normalize platelet counts. Follow the dose adjustment guidelines to achieve and maintain a platelet count of ≥ 50 x 109/L.

Loss of Response to Nplate®

  • Hyporesponsiveness or failure to maintain a platelet response with Nplate® should prompt a search for causative factors, including neutralizing antibodies to Nplate®.
  • To detect antibody formation, submit blood samples to Amgen (1‑800‑772‑64361‑800‑772‑6436). Amgen will assay these samples for antibodies to Nplate® and thrombopoietin (TPO).
  • Discontinue Nplate® if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks at the highest weekly dose of 10 mcg/kg.
Adverse Reactions
Adult ITP
  • In the placebo-controlled trials of adult ITP patients, headache was the most commonly reported adverse drug reaction, occurring in 35% of patients receiving Nplate® and 32% of patients receiving placebo. Adverse drug reactions in adults with a ≥ 5% higher patient incidence in Nplate® versus placebo were Arthralgia (26%, 20%), Dizziness (17%, 0%), Insomnia (16%, 7%), Myalgia (14%, 2%), Pain in Extremity (13%, 5%), Abdominal Pain (11%, 0%), Shoulder Pain (8%, 0%), Dyspepsia (7%, 0%), and Paresthesia (6%, 0%).
  • The safety profile of Nplate® was similar across patients, regardless of ITP duration. The following adverse reactions (at least 5% incidence and at least 5% more frequent with Nplate® compared with placebo or standard of care) occurred in Nplate® patients with ITP duration up to 12 months: bronchitis, sinusitis, vomiting, arthralgia, myalgia, headache, dizziness, diarrhea, upper respiratory tract infection, cough, nausea and oropharyngeal pain. The adverse reaction of thrombocytosis occurred with an incidence of 2% in adults with ITP duration up to 12 months.
Pediatric ITP
  • The most common adverse reactions experienced by ≥ 5% of patients receiving Nplate® with ≥ 5% higher incidence in the Nplate® arm across the two placebo-controlled trials were contusion (41%), upper respiratory tract infection (31%), oropharyngeal pain (25%), pyrexia (24%), diarrhea (20%), rash (15%), and upper abdominal pain (14%).
  • In pediatric patients of age ≥ 1 year receiving Nplate® for ITP, adverse reactions with an incidence of ≥ 25% in the two randomized trials were: contusion (41%), upper respiratory tract infection (31%), and oropharyngeal pain (25%).
  • In a long-term, single arm, open label pediatric safety study, headache occurred in 78/203 patients (38%); the incidence rates of other adverse reactions were similar to those reported in the placebo-controlled studies.

Nplate® administration may increase the risk for development or progression of reticulin fiber formation within the bone marrow. This formation may improve upon discontinuation of Nplate®. In a clinical trial, one patient with ITP and hemolytic anemia developed marrow fibrosis with collagen during Nplate® therapy.

INDICATIONS

Nplate® is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Nplate® is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Nplate® is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Nplate® should not be used in an attempt to normalize platelet counts.

Please see full Prescribing Information and Medication Guide.

Important Safety Information

Risk of
Progression of Myelodysplastic Syndromes to Acute Myelogenous Leukemia

  • In Nplate® (romiplostim) clinical trials of patients with myelodysplastic syndromes (MDS) and severe thrombocytopenia, progression from MDS to acute myelogenous leukemia (AML) has been observed.
  • Nplate® is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than ITP.

Thrombotic/Thromboembolic Complications

  • Thrombotic/thromboembolic complications may result from increases in platelet counts with Nplate® use. Portal vein thrombosis has been reported in patients with chronic liver disease receiving Nplate®.
  • To minimize the risk for thrombotic/thromboembolic complications, do not use Nplate® in an attempt to normalize platelet counts. Follow the dose adjustment guidelines to achieve and maintain a platelet count of ≥ 50 x 109/L.

Loss of Response to Nplate®

References: 1. Data on file, Amgen; [1]; 2024. 2. Data on file, Amgen; [2]; 2024. 3. Data on file, Amgen; Number of patients treated with Nplate® from launch through to June 2024; Updated 2024.